Trier Clayton

SEC source: 0000950170-25-075784 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,306

F1 · shares: Includes 1,882 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 941 shares on August 20, 2025, 470 shares on November 20, 2025, and 471 shares on March 6, 2026, if he is a director of the Company on those dates.

F1 · balance_after: Includes 1,882 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 941 shares on August 20, 2025, 470 shares on November 20, 2025, and 471 shares on March 6, 2026, if he is a director of the Company on those dates.

SEC source: 0000950170-24-125737 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,424

F1 · price: The price reported ($95.78) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $95.15 to $96.84 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 712 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as 356 share in each of January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-063163 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,424

F1 · shares: Includes 1,424 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 356 shares on July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025, if he is a director of the Company on those dates.

SEC source: 0000950170-24-031638 · ownership.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

F1 · balance_after: Includes 400 shares of restricted stock granted under the Company's equity plans. Restrictions will lapse as to the 400 shares on April 1, 2024 subject to the grantee's continued service as director of Company on those dates.

SEC source: 0001209191-23-058676 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,400

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.11 to $92.79, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.

SEC source: 0001209191-23-057988 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,570

F1 · balance_after: Includes 800 shares of restricted stock granted under the Company equity plans. Restrictions lapse as to 400 shares on each of January 1, 2024 and April 1, 2024, subject to the grantee's continued service as a director of the Company on those dates.

SEC source: 0001209191-23-030689 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,070

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1.

SEC source: 0001209191-23-016275 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,470

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $102.60 to $102.77, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 400 shares of common stock granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on April 1, 2023, if he is a director of the Company on that dates.

SEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 3

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,840

F4 · price: The price reported is a weighted average price $89.57. The shares were sold in multiple transactions at prices ranging from $89.50 to $89.60 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates.

SEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 2

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,240

F3 · price: The price reported is a weighted average price $88.09. The shares were sold in multiple transactions at prices ranging from $87.80 to $88.41 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates.

SEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,780

F1 · price: The price reported is a weighted average price $88.68. The shares were sold in multiple transactions at prices ranging from $88.45 to $88.95 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates.

SEC source: 0001209191-22-029975 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,580

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2022, October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1.

SEC source: 0001209191-21-038140 · doc4.xml · nonDerivative · entry 3

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,980

F2 · balance_after: Includes 1,480 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 370 shares on each of July 1, 2021, October 1, 2021, January 1, 2022 and April 1, 2022, if he is a director of the Company on those dates.

SEC source: 0001209191-21-038140 · doc4.xml · nonDerivative · entry 2

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,034

F2 · balance_after: Includes 1,480 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 370 shares on each of July 1, 2021, October 1, 2021, January 1, 2022 and April 1, 2022, if he is a director of the Company on those dates.

SEC source: 0001209191-21-038140 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,061

F1 · price: The price reported is a weighted average price ($119.92). The shares were sold in multiple transactions at prices ranging from $119.91 to $119.99 per share, inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,480 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 370 shares on each of July 1, 2021, October 1, 2021, January 1, 2022 and April 1, 2022, if he is a director of the Company on those dates.

SEC source: 0001209191-21-036309 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,480

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.21 to $120.39 per share. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,480 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 370 shares lapsed on each of July 1, 2021, October 1, 2021, January 1, 2022 and April 1, 2022, if he is a director of the Company on those dates.

SEC source: 0001209191-21-033897 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,680

F1 · shares: The 1,480 shares of common stock was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 370 shares lapsed on each of July 1, 2021, October 1, 2021, January 1, 2022 and April 1, 2022, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,480 shares of restricted stock granted under the Company equity plans mentioned in Note 1.

SEC source: 0001209191-20-061363 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,200

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on those dates.

SEC source: 0001209191-20-047421 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,950

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-19-045862 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,100

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.80 to $135.91 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,200 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-045862 · doc4.xml · nonDerivative · entry 2

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,350

F3 · shares: Bona fide gift.

F2 · balance_after: Includes 1,200 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

SEC source: 0001209191-19-032016 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,850

F1 · shares: The 1,600 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares discussed in Note 1.

SEC source: 0001209191-18-047667 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,250

F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019.

SEC source: 0001209191-18-032529 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.

SEC source: 0001209191-17-065206 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

F1 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Trier is a director of the Company on those dates.

SEC source: 0001209191-17-065622 · doc4a.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.80 - $72.30, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Trier is a director of the Company on those dates.

SEC source: 0001209191-17-055734 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,750

F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 1,000 on the date of grant, October 3, 2017, for the remaining 1,000 shares 500 will lapse on each of January 1, 2018, and April 1, 2018, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 2,000 shares discussed in Note 1.